Island's $6.4B, Precision Neuro's $250M & the AI Control-Point Bet
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Island's $6.4B, Precision Neuro's $250M & the AI Control-Point Bet
-
Letto da:
-
Di:
(00:01:10) AI Defensibility: Models to Moats
(00:01:41) Pilgrim's Biosurveillance Seed Round
(00:02:24) Precision Neuroscience's $250M Round
(00:02:54) Kasvu, Basecamp, and Biotech Bets
(00:03:39) Semiconductor Power Delivery and Closing Watchpoints
Capital is rotating. Not toward AI applications, but toward the control points that govern them — and today's stories map exactly where institutional money is landing.
Island raised $400M at a $6.4B valuation, up sharply from $4.8B just months ago. The repricing reflects a specific thesis: as AI agents operate through browsers alongside humans, the browser becomes the one surface where security policy, compliance, and access management can actually be enforced. Evolution Equity is betting that operational moat — deep IT integrations, procurement relationships, compliance infrastructure — is worth more than any algorithmic advantage right now.
Precision Neuroscience closed $250M backed by Pershing Square and ARK Invest, funding the transition from research settings to clinical deployment for minimally invasive neural implants. The 'minimally invasive' framing is deliberate — it's the commercial wedge into hospital systems and insurance coverage.
Pilgrim closed a $25M seed for ARGUS, an environmental biosurveillance platform combining air sampling with genomic sequencing. Buckley Ventures led, with backing connected to Anthropic's red-team community. Biological threat detection is being framed as recurring infrastructure.
In biotech, Helsinki-based Kasvu raised €30M Series A for a neuroplasticity compound targeting TrkB receptors — the psychedelic mechanism, without the psychedelic experience. Basecamp Research closed $140M Series C for AI-driven drug discovery trained on proprietary biological data.
Two Chinese semiconductor raises — Langxi Technology and Puxi Optoelectronics — signal that AI performance scaling is now constrained by power delivery and packaging, not raw compute density.
Watchpoints: whether Island's browser thesis becomes standard Fortune 500 procurement, and whether Pilgrim generates a replicable biosurveillance commercial framework.
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione